Free Trial

Iradimed Q4 2023 Earnings Report

Iradimed logo
$60.33 +1.16 (+1.96%)
As of 04:00 PM Eastern

Iradimed EPS Results

Actual EPS
$0.36
Consensus EPS
$0.37
Beat/Miss
Missed by -$0.01
One Year Ago EPS
N/A

Iradimed Revenue Results

Actual Revenue
$17.45 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Iradimed Announcement Details

Quarter
Q4 2023
Time
N/A

Conference Call Resources

Conference Call Audio

Iradimed Earnings Headlines

IRADIMED Reports Record Revenues for Q4 2024 and Full-Year 2024
24/7 Automated Profits in Crypto
What if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast world of passive crypto income, where you set up a dependable income stream that works for you, whether you're at your computer or living your life.
Iradimed (IRMD) Gets a Buy from Lake Street
Iradimed Reports Growth In Q4, FY Preliminary Revenues
iRadimed reports preliminary Q4 revenue $19.2M-$19.4M
See More Iradimed Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Iradimed? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Iradimed and other key companies, straight to your email.

About Iradimed

Iradimed (NASDAQ:IRMD) Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging compatible medical devices. It also provides a non-magnetic Intravenous infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL.

View Iradimed Profile

More Earnings Resources from MarketBeat